Explore the Agenda

7:30 am Registration & Coffee

8:20 am Chair’s Opening Remarks

Chief Patient Officer, ISPEP

8:30 am Measurement from the Chief Patient Officer’s Perspective: Creating Organisational Frameworks that Combine Business Objectives with Unmet Patient Needs

Chief Patient Officer, ISPEP
  • Building end-to-end patient engagement strategies that integrate business priorities with unmet patient needs
  • Measuring dual impact by tracking both business-value and patient-value outcomes
  • Demonstrating results effectively to internal leadership, regulators, and external stakeholders

Measuring the True Impact of Patient Engagement Across the Entire Product Lifecycle

9:00 am Setting the Foundation for Smarter Development by Measuring Patient Impact in Pre-Clinical Decision-Making

Patient-Centered Outcomes Research Chapter Lead, UK Site Head for Data Sciences, Roche
  • Demonstrating how early patient input quantifiably reduces late-stage protocol changes and costly trial attrition
  • Highlighting methods to capture patient-reported insights when standard clinical KPIs are not yet defined
  • Real-world examples showing measurable improvements in Target Product and Target Value Profiles driven by early patient data

9:30 am The Quantitative Side of Patient-Centric Early Research

Research & Development, Chief Patient Officer, Servier
  • Discussing the value of patient engagement in early research to explore uncover and neglected key symptoms
  • Converting qualitative patient input into quantitative metrics and actionable KPI symptoms 
  • Highlighting approaches that ensure patient input drives decisions long before clinical development 

10:00 am Evaluating Patient Engagement to Accelerate Program Success & Feasibility

Associate Director, Senior Global Program Manager, Viatris
  • Exploring how patient engagement may influence recruitment timelines, retention rates, and overall program success
  • Addressing the long-standing challenge of evaluating patient engagement by introducing objective metrics that move beyond anecdotal reporting
  • Connecting early patient involvement with improved trial outcomes and program long-term success, while recognising the challenges in attributing direct impact

10:30 am Morning Break & Speed Networking

Join our speed networking session tailored for Patient Engagement professionals, like yourselves, to connect with fellow industry peers to facilitate rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections within the space

11:30 am From Reporting to Real Impact: Measuring Patient Engagement in the Evolving ESG Landscape

Global Patient Partnerships Lead, Roche
Senior Program Director, PFMD
  • An overview of the latest CSRD changes and how they open the door to stronger, more structured PE reporting
  • Insight into how other global ESG frameworks – including the UN Sustainable Development Goals (SDGs), Social Return on Investment (SROI), and others – are being leveraged to assess and report on engagement with patients and communities
  • A first look at PFMD’s third annual ESG landscaping analysis, offering real-world examples and trends across the industry

12:00 pm Walking the Talk: Strategies for Successful Drug Development Outcomes in the Era of Patient Focused Drug Development

Patient Centered Outcomes Research (P-COR) Chapter Lead, Bayer
  • Highlighting the importance of involving patients in the drug development process early, from the design of clinical trials to the selection of meaningful clinical outcome assessments (COAs), ensuring their perspectives and experiences are prioritised as emphasised in FDA and EMA regulatory guidelines
  • Discussing how latest research methods (e.g. in-trial interviews) and technologies (e.g. electronic COAs) can enhance the collection and reporting of patient feedback, leading to higher compliance, more accurate and truly patient centered outcomes into treatment efficacy endpoints
  • Emphasising the need for pharmaceutical companies to ensure their clinical programmes are fostering a culture of continuous improvement in drug development that aligns with patient priorities and needs, as early as Phase 1

12:30 pm Using Pre-Launch Patient Engagement Metrics to Strengthen Access & Value Strategies

Head of External Affairs, Patient Value & Access, Takeda
  • Evaluating patient input impact on payer readiness and health technology assessment strategies
  • Tracking measurable outcomes from patient engagement influencing launch planning and payer messaging
  • Addressing challenges in differentiating objective patient insights from anecdotal feedback

1:00 pm Lunch & Networking

2:00 pm Developing & Strengthening Patient Partnerships; Demonstrating the Impact of Lived-Experience Insights Across the Access to Medicine Domains

Head of Patient Advocacy, Myeloma UK
  • Measuring short, medium, and long-term patient engagement activities supporting market access
  • Developing KPIs and frameworks to evaluate patient partnership outputs
  • Reflecting on lessons learned, data and terminology limitations and refining how we advocate for ‘permission’ to invest and engage

Embedding Patient Engagement into Strategy: Frameworks to Prove Value Across Teams

2:30 pm Proving the Intangible by Translating Qualitative Patient Insights into Business Metrics

Global Senior Director, Patient Engagement & Oncology Lead, GSK
  • Combining qualitative and quantitative data to create credible evidence of patient engagement impact
  • Validating and calibrating patient-reported insights using robust methods to ensure leadership confidence
  • Framing complex qualitative data into actionable business language that drives strategic decisions

3:00 pm Afternoon Break & Networking

3:45 pm Panel Discussion: Advancing Pre-Competitive Collaboration to Standardize Patient Engagement Metrics

Head of Patient Advocacy, N/A
Global Lead for Patient engagement & Human-Centered Healthcare, Chiesi Group
Patient-Centered Outcomes Research Chapter Lead, UK Site Head for Data Sciences, Roche
  • Driving industry-wide consensus on patient engagement benchmarks to enhance credibility and comparability
  • Overcoming data-sharing, IP, and trust barriers to unlock collaborative learning and innovation
  • Leveraging insights from leading consortia to adopt proven measurement standards and accelerate sector progress

4:15 pm From Insight to Impact: Harnessing the Patient Centricity Model for Engagement Value

Patient Insights & Intelligence Lead, Novo Nordisk
  • Overview of Novo Nordisk’s journey in developing and implementing the Patient Centricity Model within organisational strategies and decision-making processes
  • Identifying and establishing metrics to quantify the organisational value and impact of patient engagement efforts
  • Sharing case studies highlighting successes and challenges in capturing patient insights and translating them into actionable strategies
  • Discussing best practices and collaborative approaches to scale patient engagement initiatives across different functions, driving organisational alignment and enhanced patient outcomes

4:45 pm Chair’s Closing Remarks

Chief Patient Officer, ISPEP

5:00 pm End of Conference Day One